The human papillomavirus type 16 (HPV-16) E7 and adenovirus (Ad) EIA oncoproteins share a common pathway of transformation. They disrupt the cell cycle G~ phase-specific protein complex containing the E2F transcription factor and the regulatory protein Rbl, the retinoblastoma tumour suppressor gene product. In the G1 and S phases of the cell cycle, E7 and E1A bind two other cellular complexes containing the Rbl-related protein p107 and E2F. Ad E1A disrupts both complexes and releases active E2F. In contrast, HPV-16 E7, although it efficiently binds both E2F-pl07 complexes, causes dissociation of the G 1 phase complex only. Using chimeric proteins of HPV-16 E7 and Ad E1A we were able to demonstrate that the ability of E1A to disrupt both G1 and S phase E2F-pl07 complexes is not due to the higher concentration ofAd E1A in the cell, but is an intrinsic property of the Ad E1A transforming region. These data suggest that E1A and E7 may function in cellular transformation in similar, but not identical ways.
The human papillomavirus type 16 (HPV-16) E7 and adenovirus (Ad) EIA oncoproteins share a common pathway of transformation. They disrupt the cell cycle G~ phase-specific protein complex containing the E2F transcription factor and the regulatory protein Rbl, the retinoblastoma tumour suppressor gene product. In the G1 and S phases of the cell cycle, E7 and E1A bind two other cellular complexes containing the Rbl-related protein p107 and E2F. Ad E1A disrupts both complexes and releases active E2F. In contrast, HPV-16 E7, although it efficiently binds both E2F-pl07 complexes, causes dissociation of the G 1 phase complex only. Using chimeric proteins of HPV-16 E7 and Ad E1A we were able to demonstrate that the ability of E1A to disrupt both G1 and S phase E2F-pl07 complexes is not due to the higher concentration ofAd E1A in the cell, but is an intrinsic property of the Ad E1A transforming region. These data suggest that E1A and E7 may function in cellular transformation in similar, but not identical ways.
There is a strong association between some types of human papillomavirus (HPV) and cervical cancer. In most cases, HPV-16 or HPV-18 DNA has been found in malignant cells (for review see zur Hausen, 1991) . The two early genes, E7 and E6, are responsible for malignant cellular transformation (Matlashewski et al., 1987) . In fact, both of these genes are consistently retained in the DNA of cervical cancer cells and are actively transcribed. Several interactions between the two viral proteins and cellular proteins have been characterized. The HPV-16 E7 gene product, a small nuclear phosphoprotein, is the major transforming protein of the virus. E7 cooperates with the activated ras gene product in the transformation of primary rodent cells or with E6 in the immortalization of human keratinocytes, the natural host cell for the virus (for review see Mansur & Androphy, 1993) . E7 is structurally and functionally related to adenovirus (Ad) E1A protein (Phelps et al., 1988) and on this basis can be divided into three domains: CR1 and CR2, which are in the N-terminal region, and CR3, which is in the Cterminal region. CR2 contains the LXCXE domain * Author for correspondence. Fax +44 1223 333 346.
involved in the binding of the retinoblastoma protein (Rbl). Both viral oncoproteins bind the Rb family proteins Rbl, p107 and p130 (White et al., 1988 (White et al., , 1989 Dyson et al., 1989; Davies et al., 1993) . These cellular proteins are involved in control of the cell cycle by interacting with and inhibiting transcription factors such as E2F Bandara & La Thangue, 1991; Chellappan et al., 1991; Cobrinik et aI., 1993) . E2F, which so far comprises a family of six proteins, is involved in controlling transcription of several genes which are required in DNA replication. Some E2F proteins bind Rbl whilst others bind only to Rbl-related proteins, such as p107 (Beijersbergen et al., 1994; Ginsberg et al., 1994; La Thangue, 1994) . Rbl is phosphorylated in a cell cycle-dependent manner and it is the hypophosphorylated form which is associated with the transcription factor E2F-1 in G 1 phase (for review see Goodrich & Lee, 1993) . Ad E1A and HPV-16 E7 bind the hypophosphorylated form of Rbl with consequent release of free E2F, which is then able to activate the transcription of genes required in the GI-S transition Bandara & La Thangue, 1991; Chellappan et al., 1991; Mudryj et al., 1991; Phelps et al., 1991) . The Rbl-related protein p107 is also associated with E2F (Cao et at., 1992; al., 1992a al., , Shirodkar et al., 1992 , regulating its transcription activity (Schwarz et al., 1993; Zhu et al., 1993) and the E2F-pl07 complex has also been found associated with cyclin E and cyclin A/cdk2 in the G 1 and S phases, respectively (Lees et al., 1992) . Ad E1A and HPV-16 E7 bind p107, but the consequences of these interactions are different. When Ad E1A binds p107 it releases free active E2F from both G1 and S complexes, whereas HPV-16 E7, although it associates with p107, clearly does not cause dissociation of the E2F-pl07 complex in S phase (Arroyo et al., 1993; Pagano et al., 1992b) . Complexes containing E7, E2F, p107 and cyclin A/cdk2 are therefore present in cells expressing the E7 gene. Nothing is known about the existence of the G1 E2F-pl07 complex in E7-expressing cells. Lam et al. (1994) have shown that HPV-16 E7 activates the transcription of B-myb, a gene which is required for G1 S progression, apparently by binding to p107. We have performed a detailed analysis of E2F-p 107 complexes by gel retardation in extracts of cells containing Ad E1A or HPV-16 E7. Retrovirus constructs expressing Ad E1A or HPV-16 E7 genes were transfected using the calcium phosphate coprecipitation method into a producer cell line (GPE) and selected in G418 for 3-4weeks. The progeny virus was then used to infect NIH 3T3 cells in presence of polybrene (8 gg/ml). Cells were grown in G418 and after 4 weeks colonies were plated in soft agar to select high E7-or E1A-producer cells. The trans-formed colonies were isolated and the presence of Ad E1A or HPV-16 E7 in corresponding cell lines NIH 3T3 E1A and NIH 3T3 E7 was determined by direct immunoblotting of total cell extracts ( Fig. 1) . We then performed a gel retardation assay to analyse the E2F-pl07 complexes in NIH 3T3, NIH 3T3 E1A and NIH 3T3 E7 cells. Extracts from asynchronously growing ceils were incubated with a 32P-labelled otigonucleotide specific for the E2F DNA-binding site from the Ad E2 promoter. DNA-protein complexes were resolved on native acrylamide gels and detected by autoradiography. As can be seen in Fig. 2 (a) , NIH 3T3 cell extract contained two complexes that were supershifted with an antibody specific to p107. Only the upper pl07-containing band could be disrupted by an anticyclin A antibody. As expected, these two E2F-pl07 complexes are present at different times during the cell cycle. NIH 3T3 cells were blocked in the G0-G 1 phase of the cell cycle by serum starvation and subsequently released by the addition of serum• Cells were collected for E2F gel retardation analysis after 5 and 10 h, which corresponds approximately to G a phase and the beginning of S phase, respectively, as shown by FACScan analysis and pH]thymidine incorporation (data not shown). Gel retardation assays with NIH 3T3 cells extracted 5 and 10h after serum starvation release demonstrated that the upper band, disrupted by an anti-cyclin A antibody, was present in S phase (Fig. 2b) .
The G 1 and S phase E2F p107 complexes are not confined to NIH 3T3 cells; in fact the same complexes were observed in cellular extracts of human primary foreskin fibroblasts and HaCat cells by gel retardation analysis (data not shown). In agreement with previous data, E1A and E7 also have different activities in NIH 3T3 cells with respect to the disruption of the E2F-pl07 complexes (Arroyo et al., 1993; Pagano et al., 1992b) . In NIH 3T3 E1A cells both E2F-pl07 complexes were absent (Fig. 2c ), whereas in cell extract from E7expressing cells (NIH 3T3 E7) only one of the two E2F p107 bands was detectable (Fig. 2c ). This supershifted band comigrated with the S phase E2F-pl07cyclin A complex ( Fig. 2 cO and was disrupted by an E7specific monoclonal antibody and by anti-cyclin A antibody, suggesting that both proteins were present in the E2F-pl07 complex ( Fig. 2c; data not shown). The G1 E2F p107 band was not visible in E7 extracts, even after a long exposure of the film. Thus, although E7 is synthesized at low levels in these cells (at least 5-10 times lower than in CaSki cells; data not shown), it disrupted the G a phase E2F-pI07 complex very efficiently but not the S phase E2F pl07-cyclin A complex. There are two possibilities why the two viral oncoproteins have such different activities in the disruption of E2F-pl07 complexes: (i) the disruption of S phase E2F-pl07 complex occurs only because Ad E1A is present at a much higher concentration than HPV-16 E7 in cells (Fig. 1) , or (ii) the ability to disrupt the S phase E2F-p107 complex is an intrinsic property of Ad E1A.
To distinguish between these alternatives we constructed three chimeric proteins, fusing the N-and C-terminal regions of HPV-16 E7 and Ad E1A in all possible combinations. As shown in Fig. 3(a) , the junction between the two viral proteins was positioned after the casein kinase II site. Two E7-E1A proteins were constructed: E7/E1A289, containing the E1A CR3 region, and E7/E1A243, which lacks the CR3 CXXC motifs. The third chimeric protein was obtained by fusing the N-terminal region of Ad E1A with the Cterminal region of HPV-16 E7. The chimeric genes were generated by overlap PCR, cloned into a retrovirus vector (pMXSV neo-18), sequenced and introduced in NIH 3T3 cells as described above. All three chimeric proteins retained the ability of native oncoproteins to transform NIH 3T3 cells (data not show). Colonies were isolated from soft agar plates and maintained under selection of G418. The concentration of the different proteins in the stably transfected NIH 3T3 cells was determined by direct immunoblotting using two different Ad E1A-specific monoclonal antibodies, M37 and M73, which react with the N-and C-terminal regions of the protein, respectively. Ad E1A was included in both immunoblots as an internal standard. As shown in Fig.  3 (b) all proteins appeared to be synthesized at approximately the same level. Before analysing the E2F-pl07 complexes in cellular extracts containing the chimeric proteins by gel retardation assay, it was important to check that they retained the ability of the parental proteins to interact with p107 and the other cellular proteins. Cell extracts from NIH 3T3 cells and NIH 3T3 cells containing the three different chimeric proteins or E1A289 were immunoprecipitated with E1A-or E7specific antibodies; the presence of p107, cyclin A and cdk2 was determined by immunoblotting. As shown in Fig. 4 , all three cellular proteins were associated with E7/E1A289, E7/E1A243 and E1A/E7, suggesting that the main binding properties of Ad E1A and HPV-16 E7 are conserved in the chimeric products. Next we analysed the E2F-p107 complexes in the cells containing the chimeric proteins. Gel retardation analysis with cellular extracts containing the E7 E1A chimeric proteins (ET/E1A289 and E7/E1A243) showed the same slower migrating band present in the E7 cellular extracts. This band was super-shifted by the pl07-specific monoclonal antibody (Fig. 5 ). Incubation of E7/E1A289 cellular extracts with the 32P-labelled E2F DNA consensus site in the presence of M73 antibody resulted in a reduction of the E2F-p107 band, suggesting that the chimeric protein was able to bind to the p107 complex without disrupting it, as in the case of HPV-16 E7. In contrast the E1A-E7 cell extract did not contain any complex which was super-shifted with p107 antibody. E1A-E7 protein, although present in the cell at a much lower concentration than Ad E1A, was still able to disrupt both E2F-pl07 complexes (Fig. 5 ). All NIH 3T3 cells containing the chimeric proteins had approximately the same level of p 107, as indicated by immunoblotting (data not shown) and by analysis of the chimeric protein immunopellets (Fig. 4) . Thus, the absence of the E2F-p107 complexes in NIH 3T3 E7-E1A cells was not due to the lower concentration of p107.
These results show clearly that the different activity of Ad E1A and HPV-16 E7 in disruption of the E2F-pl07 complex is not related to the concentration of the viral oncoproteins in the cell, but is due to an intrinsic property of the Ad E 1A N-terminal transforming region. The G 1 phase E2F-pl07 complex may be involved in
E7/E 1 A243 Fig. 5 . E2F gel retardation assay of the NIH 3T3 cell extracts containing the three chimeric proteins. Extracts were prepared from NIH 3T3 E7/E1A289, NIH 3T3 E1A-E7 or NIH 3T3 E7/E1A243 cells and processed as described in Fig. 2 . The antibodies used in the gel retardation assay are indicated.
deregulation of cellular growth control by HPV and Ad. Both viruses have to disrupt the G 1 phase E2F-pl07 complex in order to stimulate progression of the ceil cycle. Disruption of the E2F-pl07-cyclin A complex by E1A may be required for a specific function of the Ad life cycle, for instance transactivation of the E2 gene. The difference between the two E2F-pl07 complexes in their behaviour with E7 is not entirely clear. It is possible that cyclin A/cdk2, when activated in S phase, phosphorylates the E2F-pl07 complex preventing the dissociation induced by E7. Alternatively the two E2F-p 107 complexes may contain different members of the E2F protein family. The G 1 E2F~107 complex does not contain cyclin E, since we did not observe any band super-shifted or disrupted by anti-cyclin E antibody in our gel retardation assays (data not shown). The physiological function of the interaction of E7 with the E2F-pl07 complex in S phase is not yet clear but may result in subtle differences between Ad and HPV in the type of transformation produced. This could be linked to the fact that only HPV is involved in human cancer.
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